Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cartesian Therapeutics (NAS:RNAC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cartesian Therapeutics Days Sales Outstanding Related Terms
Cartesian Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cartesian Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics Days Sales Outstanding Chart
RNAC vs FATE, FULC, BCYC: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Cartesian Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cartesian Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cartesian Therapeutics's Days Sales Outstanding falls into.
Cartesian Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics (RNAC) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cartesian Therapeutics and its competitors. Over the past decade, Cartesian Therapeutics' Days Sales Outstanding has ranged from 23.46 to 379.11. According to the industry distribution chart, Cartesian Therapeutics ranks #675 out of 841 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Cartesian Therapeutics' Days Sales Outstanding too high?
Cartesian Therapeutics' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 23.46 to a high of 379.11. Based on the distribution chart, Cartesian Therapeutics ranks #675 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cartesian Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cartesian Therapeutics' Days Sales Outstanding compare to FATE and FULC?
According to the Biotechnology industry distribution chart, Cartesian Therapeutics ranks #675 out of 841 companies for Days Sales Outstanding. This places Cartesian Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Historically, Cartesian Therapeutics' own Days Sales Outstanding has ranged from 23.46 to 379.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cartesian Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cartesian Therapeutics's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cartesian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cartesian Therapeutics (RNAC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $8.43 — trading 2910.7% above its estimated fair value. The current Days Sales Outstanding is 0.00. Cartesian Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cartesian Therapeutics (RNAC), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cartesian Therapeutics (RNAC) Overvalued in 2026?
Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued.
The current stock price of $8.43 is trading 2910.7% above its estimated GF Value™ of $0.28.
GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.
Key valuation signals for RNAC:
Days Sales Outstanding: 0.00
GF Value™: $0.28 vs. price of $8.43 (2910.7% above fair value)
No single metric tells the full story. See the RNAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
28GF Score
Get the complete analysis for RNAC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNAC has been successfully added to your 
